Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30
Leerink Partners analyst Andrew Berens initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Outperform rating and announces Price Target of $30.
A big analyst firm says they like Kazia Therapeutics and think it could be worth $30. When expert watchers start following a company, it means they see something interesting to study.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.